Pasithea Therapeutics (KTTA) Change in Cash (2021 - 2026)

Pasithea Therapeutics has reported Change in Cash for 6 years, with the latest figure at -$4.8 million in Q1 2026.

• Quarterly Change in Cash fell 200.88% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.2 million (up 777.26% YoY) and the FY2025 annual result came in at $48.3 million, up 613.77% from the prior year.
• Change in Cash eased to -$4.8 million in Q1 2026 per KTTA's latest filing, from $51.0 million in the prior quarter.
• Over five years, Change in Cash peaked at $51.0 million in Q4 2025 and troughed at -$9.3 million in Q4 2022.
• A 5-year average of -$141205.6 and a median of -$3.2 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2025: Change in Cash slumped 423.6% in 2022, then soared 2192.99% in 2025.
• Over 5 years, Change in Cash stood at -$9.3 million in 2022, then surged by 64.98% to -$3.3 million in 2023, then rose by 25.05% to -$2.4 million in 2024, then jumped by 2192.99% to $51.0 million in 2025, then plunged by 109.32% to -$4.8 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$4.8 million, $51.0 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.